The Technical Analyst
IMV Inc [IMV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
IMV Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.823
America/New_York / 28 apr 2023 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.63 mill |
| EPS: | -4.55 |
| P/E: | -0.181 |
| Earnings Date: | Aug 09, 2023 |
| SharesOutstanding: | 11.71 mill |
| Avg Daily Volume: | 0.152 mill |
| RATING 2023-05-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.181 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.181 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0521 - 0.188 ( +/- 56.62%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.823 (0.00% ) |
| Volume | 0.0449 mill |
| Avg. Vol. | 0.152 mill |
| % of Avg. Vol | 29.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IMV
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Latest Press Releases
2023-07-26 07:05:00 - Press Release
Imv Inc. Announces Update On Ccaa Proceedings And Sales And Investment Solicitation Process
Dartmouth, nova scotia--(business wire)--imv inc. (the “company” or “imv”), recently announced an update on the sales and investment solicitation process (the “sisp”) implemented as part of its ongoing proceedings under the companies' creditors arrangement act (the “ccaa”). as previously disclosed, imv initiated the ccaa proceedings on may 1, 2023, to facilitate the restructuring of the company with the goal of implementing a transaction. since then, the company has been diligently working with.
2023-05-08 16:30:00 - Press Release
Imv Receives Nasdaq Delisting Notice
Dartmouth, nova scotia & cambridge, mass.--(business wire)--imv inc. (the “company” or “imv”) (nasdaq: imv; tsx: imv), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel dpx® platform to treat solid and hematologic cancers, today announced that it was notified by the listing qualifications department of the nasdaq stock market llc ("nasdaq") that nasdaq, in accordance with nasdaq listing rules 5101, 5110(b) and im-5101-1, has in ex.
2023-05-02 16:15:00 - Press Release
Horizon Technology Finance Announces First Quarter 2023 Financial Results
- first quarter 2023 net investment income per share of $0.46; nav per share of $11.34 - - debt portfolio yield of 16.3% - - grew portfolio year over year by 39% to $715 million - - horizon platform ends quarter with committed backlog of $218 million, including $187 million in hrzn commitments - - declares regular monthly distributions totaling $0.33 per share - farmington, conn. , may 2, 2023 /prnewswire/ -- horizon technology finance corporation (nasdaq: hrzn) ("hrzn", "horizon" or the "company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the first quarter ended march 31, 2023.
2023-05-01 12:30:00 - Press Release
Imv Initiates Restructuring Proceedings Under The Ccaa To Complete The Review Of Its Strategic Alternatives
Dartmouth, nova scotia & cambridge, mass.--(business wire)---- $imv #cancervaccine--imv inc. (the “company” or “imv”) (nasdaq: imv; tsx: imv), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel dpx® platform to treat solid and hematologic cancers, announced today that the nova scotia supreme court (the “court”) has issued an initial order (the “initial order”) granting the company and its subsidiaries protection under the companies' creditors arrangement.
2023-03-31 16:15:00 - Press Release
Imv Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Dartmouth, nova scotia & cambridge, mass.--(business wire)---- $imv #cancervaccine--imv inc. (“imv” or the “company”) (nasdaq: imv; tsx: imv), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel dpx® platform to treat solid and hematologic cancers, today announced that on march 29, 2023, imv inc.
Latest News
2023-03-16 11:02:08 - Seeking Alpha
IMV Inc. (IMV) Q4 2022 Earnings Call Transcript
IMV Inc. (NASDAQ:IMV ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Doug Loe - Leede Jones Gable Operator Good day and thank you for standing by.
2023-03-09 07:05:00 - Business Wire
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results.
2022-11-12 09:25:28 - Seeking Alpha
IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript
IMV, Inc. (NASDAQ:IMV ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Joseph Pantginis - H.C. Wainwright & Co. Paul Stewardson - IA Capital Markets Operator Good day and thank you for standing by.
2022-11-08 07:05:00 - Business Wire
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
2022-09-01 07:05:00 - Business Wire
IMV Inc. to Present at Two Investor Conferences in September
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be presenting at two investor conferences in September. Please find additional details on the conferences below. H.C. Wainwright 24th Annual Global Investment Conference, New York City
2022-08-11 14:17:04 - Seeking Alpha
IMV Inc. (IMV) CEO Andrew Hall on Q2 2022 Results - Earnings Call Transcript
IMV Inc. (NASDAQ:IMV ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Brittany Davison - Senior Vice President of Finance Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Medical Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the IMV Second Quarter 2022 Earnings Call.
2022-08-04 07:05:00 - Business Wire
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 second quarter financial and operational results. Financial analysts are invited to join
2022-05-17 08:05:00 - Business Wire
IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022 in Miami, FL. H.C. Wainwright Global Investmen
2022-05-13 12:13:05 - Seeking Alpha
IMV Inc. (IMV) CEO Andrew Hall on Q1 2022 Results - Earnings Call Transcript
IMV Inc. (NASDAQ:IMV ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Andrew Hall – Chief Executive Officer Jeremy Graff – Chief Medical Officer Brittany Davison – Senior Vice President, Finance Joy Bessenger – Senior Vice President, Investor Relations & Corporate Strategy Conference Call Participants Joseph Pantginis – H.C. Wainwright & Co. Nick Abbott – Wells Fargo Securities Brandon Folkes – Cantor Fitzgerald Paul Stewardson – iA Capital Markets Joy Bessenger Good morning, everyone.
2022-05-06 07:05:00 - Business Wire
IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company's 2022 first quarter financial and operational results. Financial analysts are invited to join the con